ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,014.15
-0.16%
US Tech 100
16,941.20
-0.54%
Dow Jones
37,763.84
0.03%
Brent Oil
86.565
-0.48%
Bitcoin
62,725.21
2.35%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Inventiva Sa (0RNK) Quote

Inventiva Sa

Inventiva Sa (0RNK)

LSE
7.62
0.00
(0.00%)
Closed April 18 11:30AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
7.62
Bid
0.00
Ask
0.00
Volume
510
0.00 Day's Range 0.00
7.62 52 Week Range 7.62
Market Cap
133.143M
Previous Close
7.62
Open
-
Last Trade
255
@
3.16
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
831
Shares Outstanding
42,134,000
Dividend Yield
-
PE Ratio
-1.21
Earnings Per Share (EPS)
-2.62
Revenue
23.16M
Net Profit
-110.43M

About Inventiva Sa

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.inventivapharma.com
Headquarters
Daix, Fra
Founded
1970
Inventiva Sa is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0RNK. The last closing price for Inventiva was 7.62 €. Over the last year, Inventiva shares have traded in a share price range of 7.62 € to 7.62 €.

Inventiva currently has 42,134,000 shares outstanding. The market capitalization of Inventiva is 133.14 € million. Inventiva has a price to earnings ratio (PE ratio) of -1.21.

0RNK Latest News

More News

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») Daix (France), Long Island City (New York, United States), le 3 avril...

April 03 2024
GlobeNewswire Inc.

Inventiva announces the nomination of Andre Turenne as Director

Inventiva announces the nomination of Andre Turenne as Director Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the...

March 28 2024
GlobeNewswire Inc.

Inventiva publie ses résultats annuels 2023

Inventiva publie ses résultats annuels 2023 Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022Trésorerie et...

March 27 2024
GlobeNewswire Inc.

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva...

March 22 2024
GlobeNewswire Inc.

Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2

Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète...

March 18 2024
UK Regulatory

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D LEGEND achieved its primary...

March 18 2024
UK Regulatory

Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2

Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 Daix (France...

March 13 2024
UK Regulatory

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D Daix (France), Long Island City (New York, United...

March 13 2024
UK Regulatory

Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH  

Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH   Inventiva a levé la pause volontaire du screening et de la randomisation...

March 07 2024
UK Regulatory

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed Inventiva has lifted the voluntary pause on screening and randomization in...

March 07 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1007.627.627.621947.62DE
4007.627.627.6211797.62DE
12007.627.627.628317.62DE
26007.627.627.6213927.62DE
52007.627.627.6248447.62DE
156007.627.627.6228327.62DE
260007.627.627.6247467.62DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AGBAAGBA Group Holding Ltd
$ 1.01
(152.50%)
105M
TIRXTian Ruixiang Holdings Ltd
$ 0.8936
(84.34%)
55.67M
BPTHBio Path Holdings Inc
$ 5.5657
(71.78%)
75.23M
ISPCiSpecimen Inc
$ 0.3499
(64.27%)
8.66M
XPONExpion360 Inc
$ 2.6786
(38.79%)
9.63M
INVZWInnoviz Technologies Ltd
$ 0.1675
(-35.58%)
501
WISAWiSA Technologies Inc
$ 6.29
(-32.00%)
14.12M
RCATRed Cat Holdings Inc
$ 1.0011
(-29.50%)
3.27M
STISolidion Technology Inc
$ 1.4096
(-28.81%)
418.63k
AILEiLearningEngines Holdings Inc
$ 7.24
(-27.60%)
39.39k
SINTSiNtx Technologies Inc
$ 0.0517
(38.61%)
371.56M
SQQQProShares UltraPro Short QQQ
$ 12.085
(1.90%)
128.79M
AGBAAGBA Group Holding Ltd
$ 1.01
(152.50%)
105M
BPTHBio Path Holdings Inc
$ 5.5657
(71.78%)
75.23M
TSLATesla Inc
$ 149.7961
(-3.64%)
71.18M

Discussion

View Full Feed
drugmanrx drugmanrx 3 minutes ago
You are way over thinking this.

Before Abbie came to SOHM , ABBIE was considered a failure(could be as simple as too far ahead of its time). Look how long it took Stem cells therapy to become common medical practice.

In 1958 the French oncologist, Georges Mathé, perform
SHMN
fuagf fuagf 3 minutes ago
livefree_ordie, Why make others do the work. A link would have made your post a much better one.
dukeb dukeb 3 minutes ago
The products exist so they're not vaporware. But they have no value.

No IT professional in their right mind is going to tell their boss (or their customer) that Zerify Meet, a company that is hanging on by its toenails, is a better choice when compared to Microsoft Teams, Google Meet
ZRFY
Investor2014 Investor2014 3 minutes ago
Are you asking that because you hope the schizo trial will save your $AVXL investment?
AVXL
Tstorm Tstorm 3 minutes ago
$IWAL - .037 gone, .038 up
IWAL
Monksdream Monksdream 3 minutes ago
NVVE new 52 lo

https://investorshub.advfn.com/uimage/uploads/2024/4/18/ogwldIMG_7511.gif
NVVE
reena969 reena969 3 minutes ago
I'm uncertain about the insiders, but with the correct scanner settings, you can purchase early.... Today, a 75% profit worked well for me(I almost sold @.0006), although these trades typically take longer compared to NASDAQ plays. DRNK was more profitable than the two Pre market loading OTC this A
DRNK
trd4profit trd4profit 3 minutes ago
In a recent interview I watched for Fles, Brett Rosen said there are only about 20 auditors for the entire OTC? If that is true then I am surprised anyone files on time?
RNVA
Pazzo1212 Pazzo1212 4 minutes ago
Agreed! Much more concise and very good points not belaboring his points.

Even left time for questions this time.

Paper will come out when it comes out, and the EMA submission is in progress.

AVXL
Clootch Clootch 4 minutes ago
$PDGO
https://x.com/StockOnHighALer/status/1781019987114889471
PDGO
georgejjl georgejjl 4 minutes ago
ABSOLUTELY GREAT HIGE NEWS exactly as expected!!!

Good luck and GOD bless,
AVXL
flipper44 flipper44 4 minutes ago
I should have said, how does t+1 effect the good faith free rider rule.

It appears, though I could be wrong,

After May 28, 2024, the scenario below would apparently no longer violate the good faith free rider prohibition, because they waited until Day 2 (aka T+1)?
NWBO
georgejjl georgejjl 4 minutes ago
ABSOLUTELY GREAT HIGE NEWS exactly as expected!!!

Good luck and GOD bless,
AVXL
Jaxxm Jaxxm 4 minutes ago
Fisker Ocean and Fisker Alaska have better design better price imo
FSRN
pos_stock_hoarder pos_stock_hoarder 4 minutes ago
And the 'tards will believe them again. Vote 'em in again. Swell, huh?
tedpeele tedpeele 4 minutes ago
Zebra, you asked for evidence that commercialism is not near:

You said it is 'idle speculation', as though I have no reason at all for making such a statement, and am just saying it because I want to, but that's not it. Maybe the following will help you see my view better:
ASM
nfrequent nfrequent 4 minutes ago
Happens all the time. Hell, the 10-K was probably too good for the SEC regululator to believe it is true. LOL
RNVA
mrwilson31 mrwilson31 4 minutes ago
I think the only person here who oozes out sleezy slime is your mouth.

Those are facts.

When slime comes out and you can’t answer basic questions……we all know you are full of Horses#%t!

Your lies could fertilize many acres for years to come.
XCRT
Risk vs Reward Risk vs Reward 5 minutes ago
Didn’t think this bloodbath was over yet, just started late today.
ABQQ
makinezmoney makinezmoney 5 minutes ago
$MDCE: He doesn’t know what to do Next ?

Why the hell is this company still called Medical Care Technologies ?

Is he selling smart catheters on Infinite Auctions ?

Whatta Simp !

MDCE
ITYS ITYS 5 minutes ago
I've politely asked anyone to please explain why they feel GEVI is a good investment.

I have stated many reason why i htink its smoke n mirrors and will give YET ANOTHER EXAMPLE


Company below has been using TPC for 150 years ...SO again GEVI has nothing propriet
GEVI
MFranny MFranny 5 minutes ago
FINRA is displaying data from mandatory reporting brokerages that directly contradicts you. What's your explanation for that? Mine relies on Occam's Razor: You are mistaken.
SHMP
Risk vs Reward Risk vs Reward 5 minutes ago
It was a lie, it didn’t go anywhere because it never was. Called being a sucker…. Pink sheet deception at its finest.


Amazing to me how people think these lower markets trade with integrity and faithful business principles.

These are con artists that separate
ABQQ
Agoura Guy Agoura Guy 5 minutes ago
$497 GAP TO BE FILLED NEXT!!!!!!!!!! THE BIG QUESTION IS WILL THERE BE A TECHNICAL BOUNCE FROM IT, OR WATERFALL STRAIGHT THROUGH??????

THE BIG SELLING WILL START POST OPEX!!!!!!!



SPY
monocle monocle 5 minutes ago
Looks that way

The value of the new order is approximately $7.38 million, which the Company expects to fulfill in 2023 and 2024
IAALF

Your Recent History

LSE
0RNK
Inventiva
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved